References
- Fernandez-Romero JA . Not just HIV: preventing other viral sexually transmitted infections. Future Virol., 10(11), 1191–1194 (2015).
- Ramchandani MS , GoldenMR. Confronting rising STIs in the era of PrEP and treatment as prevention. Curr. HIV/AIDS Rep., 16(3), 244–256 (2019).
- WHO . Fact sheet on sexually transmitted infections (2019). www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)
- Owusu-Edusei K Jr , ChessonHW, GiftTLet al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex. Transm. Dis., 40(3), 197–201 (2013).
- Chen BA , BlitheDL, MuraguriGRet al. Acceptability of the woman’s condom in a Phase III multicenter open-label study. Contraception, 99(6), 357–362 (2019).
- Kempner M . ‘Female condom’ gets a genderless rebrand from FDA. www.thebodypro.com/article/female-condom-gets-a-genderless-rebrand-from-fda
- Fernandez-Romero JA , DealC, HeroldBCet al. Multipurpose prevention technologies: the future of HIV and STI protection. Trends Microbiol., 23(7), 429–436 (2015).
- Evofem Biosciences announces positive top-line results of Phase III study evaluating Amphora for hormone-free birth control 2019. https://evofem.investorroom.com/2018-12-17-Evofem-Biosciences-Announces-Positive-Top-Line-Results-of-Phase-3-Study-Evaluating-Amphora-for-Hormone-Free-Birth-Control
- Evofem Biosciences announces last patient enrolled for AMPREVENCE, the Phase IIb sexually transmitted infections trial of Amphora 2019. https://evofem.investorroom.com/2019-04-23-Evofem-Biosciences-Announces-Last-Patient-Enrolled-for-AMPREVENCE-the-Phase-2b-Sexually-Transmitted-Infections-Trial-of-Amphora
- Friedland BA , HoesleyCJ, PlagianosMet al. First-in-human trial of MIV-150 and Zinc Acetate coformulated in a carrageenan gel: safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics. J. Acquir. Immune Defic. Syndr., 73(5),489–496 (2016).
- Population council research examines new prevention approaches for most-at-risk at HIVR4P 2018. www.popcouncil.org/news/population-council-research-examines-new-prevention-approaches-for-most-at
- Lal M , LaiM, UgaonkarSet al. Development of a vaginal fast-dissolving insert combining griffithsin and carrageenan for potential use against sexually transmitted infections. J. Pharm. Sci., 107(10), 2601–2610 (2018).
- Derby N , LalM, AravantinouMet al. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo. Nat. Commun., 9(1), 3881 (2018).
- Magnan S , TotaJE, El-ZeinMet al. Efficacy of a carrageenan gel against transmission of cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, Phase IIB trial. Clin. Microbiol. Infect., 25(2), 210–216 (2019).
- Girard L , BirseK, Holmet al. Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates. Sci. Rep., 8(1), 8059 (2018).
- Hoang T , DateAA, OrtizJOet al. Development of rectal enema as microbicide (DREAM): preclinical progressive selection of a tenofovir prodrug enema. Eur. J. Pharm. Biopharm., 138, 23–29 (2019).
- Thurman AR , SchwartzJL, RavelJet al. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLoS ONE, 14(5), e0217229 (2019).
- Whaley K . Monoclonal antibodies as future MPT products. www.theimpt.org/blog-impt/item/monoclonal-antibodies-as-future-mpt-products
- Shapley-Quinn MK , ManenzheKN, AgotKet al. “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study. Int. J. Womens Health, 11, 97–107 (2019).
- Montgomery ET , BeksinskaM, MgodiNet al. End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. J. Int. AIDS Soc., 22(5), e25283 (2019).
- Critical actions to achieve the value potential of MPTs for prevention of HIV, other STIs, and unintended pregnancies among young women. Presented at: International AIDS Conference. Amsterdam, The Netherlands, July 2018. www.theimpt.org/documents/reports/MPT-WorkshopSummaryReport_AIDS2018.pdf